|Articles|September 17, 2020
In vitro glycoengineering – Suitability for BioPharma manufacturing
Author(s)Roche
Glycosylation homogeneity and pattern can be increase with cell line engineering and bioprocess optimization. But, these can be time-consuming and might compromise yield. In vitro glycoengineering can solve these problems and is independent from the cell line and the bioprocess used.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
2
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
FAQ: Understanding Biosimilars, Biobetters, and Interchangeability
5